ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Artificial sweeteners linked to risk of weight gain, heart disease and other health issues

All About Ginkgo Biloba: Benefits of This Timeless Herbal Supplement

Yarrow Oil: Here's Why It Deserves a Place in Your First-Aid Kit

Vitamin D supplement use associated with lower risk of breast cancer

Carnitine deficiency suggested as contributor to autism

Lutein — An Important Nutrient for Eye and Brain Health

White Camphor Oil: The Purest Camphor Oil

Taurine: Facts About This Crucial Amino Acid

Lutein, found in leafy greens, may counter cognitive aging

Vitamin D3 Versus D2

 
Print Page
Email Article

Dose of PTEN protein found to determine progression of prostate cancer

  [ 20 votes ]   [ Discuss This Article ]
www.ProHealth.com • October 27, 2003


Discovery may aid in diagnosis, prognosis, and possibly prevention

NEW YORK, NY – October 27 - In patients with prostate cancer, one change that can be seen at the molecular level is the loss of the PTEN tumor suppressor gene, a gene responsible for restricting cell proliferation. One or both copies of the PTEN gene are found to have been lost in 70 percent of prostate cancer patients at the time of diagnosis. It has generally been believed that one remaining copy would still protect against tumor progression to advanced metastatic cancer.

But now, for the first time, scientists at Memorial Sloan-Kettering Cancer Center have established mouse models for prostate cancer that have varying "doses" or amounts of Pten protein produced from the remaining gene. Their results show that the activity of the single Pten gene does not necessarily protect against prostate cancer. Instead, the dose determines whether the tumor will become either an aggressive cancer or take a slow path towards microscopic features of growth, but remain benign. This new understanding of the natural history of the disease could allow researchers to develop novel clinical strategies to diagnose, treat, and possibly prevent prostate cancer. This article will appear both as HTML and in print in the December 23, 2003 issue of the new, open access journal published by the Public Library of Science. It appears in PDF form online as a pre-issue publication on October 27, 2003 at www.plosbiology.org.

"We have shown that prostate cancer development is not just affected by mutation and loss of the PTEN gene but that its progression is dose-dependent on the PTEN protein, which we have measured for the first time," said Pier Paolo Pandolfi, M.D., Ph.D., Head of the Molecular and Developmental Biology Laboratory at Memorial Sloan-Kettering and the study's senior author. "Two men, each with one PTEN gene left, could have totally different disease outcomes depending on the actual dose of PTEN protein coming from that gene."

Earlier studies by Drs. Pier Paolo Pandolfi and Antonio Di Cristofano had demonstrated that loss of the Pten tumor suppressor gene in mice is responsible for a variety of malignant tumors. In humans, these were shown to include melanoma and cancers of the breast, prostate, and brain. Although the loss of just one Pten gene is enough to affect cell signaling, the loss has only been associated with slow-growing, mild lesions in the mouse prostate, comparable to early stages of the human disease. Therefore, many scientists in the field assumed that one copy of the Pten gene was still sufficient to prevent the progression to malignant cancer, in agreement with the classic definition of tumor suppressor genes.

To test this assumption, two sets of mouse models were generated. In one, the Pten gene was engineered to be removed completely from the prostate only (whole body deletion cannot be studied since it causes a lethal defect in the embryo). In the second model, mice were engineered to have only one half-active copy of the Pten gene left (roughly 30 percent protein level). In stark contrast to mice with one gene copy, the mice with no Pten gene showed aggressive, invasive prostate cancer that developed in just a short period, perhaps suggesting that the major danger in having only one copy of the Pten gene (50 percent of the normal protein level) would be to lose it (and go to zero percent). However, the mice with one half-active gene also developed prostate tumors while those with the fully active copy did not. This refuted the notion that only complete loss of the Pten gene can cause prostate cancer and instead suggests that prostate tumor development correlates closely with the actual Pten protein level.

"We analyzed the mice at a time when they should have been healthy but instead found massive prostate enlargement and cancer," explained Lloyd Trotman, Ph.D., a member of Dr. Pandolfi's Molecular and Developmental Biology Laboratory at Memorial Sloan-Kettering and a first author of the study along with Masaru Niki M.D., Ph.D. "Most importantly, this showed that dropping the Pten protein dose slightly below the 50 percent level has dramatic consequences for disease progression in just a short period."

"This study shows the consequences of serial reductions in a critical gene on prostate cancer development and progression," said Dr. Howard Scher, Chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering. "It shifts the focus from targets of the PTEN gene to the PTEN protein itself. Restoring the function of the gene to stabilize the PTEN level may be clinically beneficial. These findings also show that to understand an individual's prognosis and to optimize the therapeutic approach to an individual patient's tumor, it will be necessary to determine the absolute level of key signaling proteins, and not simply whether the protein is present or absent. Developing these methods is an area of active investigation."

The study's co-authors include Zohar A. Dotan, Jason A. Koutcher, Antonio Di Cristofano, Alan S. Khoo, and Carlos Cordon-Cardo of Memorial Sloan-Kettering; Andrew Xiao and Terry Van Dyke of University of North Carolina at Chapel Hill; Pradip Roy-Burman of Keck School of Medicine, UCLA; and Norman Greenberg of Baylor College of Medicine. The study was supported, in part, by grants from the National Cancer Institute, Memorial Sloan- Kettering, and by I.T. Hirschl/M. Weill Caulier Foundation.

Memorial Sloan-Kettering Cancer Center is the world's oldest and largest institution devoted to prevention, patient care, research and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose and treat cancer. Our specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide.



Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Ultra ATP+, Double Strength Mitochondria Ignite™ with NT Factor®


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Cocoa's Polyphenol Riches - All the Health Benefits without the Sugar, Calories or Guilt Cocoa's Polyphenol Riches - All the Health Benefits without the Sugar, Calories or Guilt
Priming Your Immune System for Cold & Flu Season Priming Your Immune System for Cold & Flu Season
Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial
Running on Empty? Fuel Up with NADH Running on Empty? Fuel Up with NADH
The New Dual Activation Pain Relief Cream The New Dual Activation Pain Relief Cream

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map